Disease spotlight: LHON

Newsletters and Deep Dive digital magazine
The FDA has approved GSK's Blujepa, the first new-mechanism oral antibiotic for uncomplicated UTIs in nearly 30 years, after a priority review.
Rare disease treatment poses distinct challenges for physicians, patients, caregivers, and pharma companies.
Every breakthrough in medicine, every new treatment that changes lives, starts with research.
The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems.
Developments in the oncology space in 2024 brought hope to both industry and patients.
The IMPACCT Real World Evidence Summit is back, offering the opportunity to bring together 50+ pharma RWE decision makers to discuss integrated evidence plans, data sharing optimization, infrastruc
With CSL Seqirus and Arcturus Therapeutics successfully developing the first approved self-amplifying RNA vaccine, the field of next generation RNAs celebrates the potential of circular and self-am
Get in-depth news, opinions and features on pharma and healthcare sent straight to your inbox
Editor's Picks